Literature DB >> 2427538

Home intravenous immunoglobulin therapy by self-administration.

E R Ashida, A Saxon.   

Abstract

Immunoglobulin replacement therapy is required by patients with certain antibody deficiency syndromes and is finding increasing application in other immune disorders such as immune thrombocytopenia. We describe the long-term home administration of intravenous gamma-globulin by seven patients themselves using a portable infusion pump. Over a period of as long as 2 years, this has proven to be effective, safe, and cost efficient and a good alternative to hospital or physicians' office-based infusions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427538     DOI: 10.1007/bf00917331

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  4 in total

1.  Long term use of intravenous immune globulin in patients with primary immunodeficiency diseases: inadequacy of current dosage practices and approaches to the problem.

Authors:  R H Buckley
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

2.  Immunoglobulin replacement therapy by slow subcutaneous infusion.

Authors:  M Berger; T R Cupps; A S Fauci
Journal:  Ann Intern Med       Date:  1980-07       Impact factor: 25.391

3.  Plasma therapy: an alternative to gamma globulin injections in immunodeficiency.

Authors:  E R Stiehm
Journal:  Birth Defects Orig Artic Ser       Date:  1975

4.  Evidence of persistent IgA/IgG circulating immune complexes associated with activation of the complement system in serum of a patient with common variable immune deficiency: anaphylactic reactions to intravenous gammaglobulin.

Authors:  V Wahn; R A Good; S Gupta; S Pahwa; N K Day
Journal:  Acta Pathol Microbiol Immunol Scand Suppl       Date:  1984
  4 in total
  15 in total

Review 1.  X-linked agammaglobulinemia.

Authors:  M E Conley; J Rohrer; Y Minegishi
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

Review 2.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Self-infusion with immunoglobulin at home.

Authors:  H Chapel; V Brennan
Journal:  J Clin Pathol       Date:  1991-05       Impact factor: 3.411

4.  Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy.

Authors:  U Nicolay; S Haag; F Eichmann; S Herget; D Spruck; A Gardulf
Journal:  Qual Life Res       Date:  2005-09       Impact factor: 4.147

Review 5.  Safety of IGIV therapy and infusion-related adverse events.

Authors:  Mark Ballow
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

6.  Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.

Authors:  Uwe Nicolay; Peter Kiessling; Melvin Berger; Sudhir Gupta; Leman Yel; Chaim M Roifman; Ann Gardulf; Florian Eichmann; Stefan Haag; Cordula Massion; Hans D Ochs
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

7.  The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

Authors:  H M Chapel; G P Spickett; D Ericson; W Engl; M M Eibl; J Bjorkander
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

8.  The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions.

Authors:  A Gardulf; H Björvell; R Gustafson; L Hammarström; C I Smith
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

Review 9.  X-linked agammaglobulinemia: lack of mature B lineage cells caused by mutations in the Btk kinase.

Authors:  C I Smith; C M Bäckesjö; A Berglöf; L J Brandén; T Islam; P T Mattsson; A J Mohamed; S Müller; B Nore; M Vihinen
Journal:  Springer Semin Immunopathol       Date:  1998

Review 10.  Intravenous immune globulin in primary immunodeficiency.

Authors:  M Haeney
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.